[HTML][HTML] Sugar-coated killer: serotype 3 pneumococcal disease
JN Luck, H Tettelin, CJ Orihuela - Frontiers in Cellular and Infection …, 2020 - frontiersin.org
Capsular polysaccharide (CPS), which surrounds the bacteria, is one of the most significant
and multifaceted contributors to Streptococcus pneumoniae virulence. Capsule prevents …
and multifaceted contributors to Streptococcus pneumoniae virulence. Capsule prevents …
New insights into the mycobacterial PE and PPE proteins provide a framework for future research
LS Ates - Molecular microbiology, 2020 - Wiley Online Library
The PE and PPE proteins of Mycobacterium tuberculosis have been studied with great
interest since their discovery. Named after the conserved proline (P) and glutamic acid (E) …
interest since their discovery. Named after the conserved proline (P) and glutamic acid (E) …
Nationwide trends of invasive pneumococcal disease in Spain from 2009 through 2019 in children and adults during the pneumococcal conjugate vaccine era
S de Miguel, M Domenech… - Clinical Infectious …, 2021 - academic.oup.com
Background Introduction of pneumococcal conjugate vaccines (PCVs) has reduced the
disease caused by vaccine serotypes in children, providing herd protection to adults …
disease caused by vaccine serotypes in children, providing herd protection to adults …
[HTML][HTML] Rapid inference of antibiotic resistance and susceptibility by genomic neighbour typing
Surveillance of drug-resistant bacteria is essential for healthcare providers to deliver
effective empirical antibiotic therapy. However, traditional molecular epidemiology does not …
effective empirical antibiotic therapy. However, traditional molecular epidemiology does not …
Effectiveness of 13-valent pneumococcal conjugate vaccine against invasive disease caused by serotype 3 in children: a systematic review and meta-analysis of …
HL Sings, P De Wals, BD Gessner… - Clinical Infectious …, 2019 - academic.oup.com
The 13-valent pneumococcal conjugate vaccine (PCV13) is the only licensed PCV with
serotype 3 polysaccharide in its formulation. Postlicensure PCV13 effectiveness studies …
serotype 3 polysaccharide in its formulation. Postlicensure PCV13 effectiveness studies …
[HTML][HTML] The metabolic, virulence and antimicrobial resistance profiles of colonising Streptococcus pneumoniae shift after PCV13 introduction in urban Malawi
U Obolski, TD Swarthout, A Kalizang'oma… - Nature …, 2023 - nature.com
Streptococcus pneumoniae causes substantial mortality among children under 5-years-old
worldwide. Polysaccharide conjugate vaccines (PCVs) are highly effective at reducing …
worldwide. Polysaccharide conjugate vaccines (PCVs) are highly effective at reducing …
Dynamic changes in otopathogens colonizing the nasopharynx and causing acute otitis media in children after 13-valent (PCV13) pneumococcal conjugate …
R Kaur, N Fuji, ME Pichichero - European Journal of Clinical Microbiology …, 2022 - Springer
The otopathogens colonizing the nasopharynx (NP) and causing acute otitis media (AOM)
have shown dynamic changes following introduction of pneumococcal conjugate vaccines …
have shown dynamic changes following introduction of pneumococcal conjugate vaccines …
Factors affecting antimicrobial resistance in Streptococcus pneumoniae following vaccination introduction
ER Watkins, A Kalizang'Oma, A Gori, S Gupta… - Trends in …, 2022 - cell.com
Streptococcus pneumoniae is a major cause of pneumonia, meningitis, and septicaemia
worldwide. Pneumococcal antimicrobial resistance (AMR) has been highlighted by the WHO …
worldwide. Pneumococcal antimicrobial resistance (AMR) has been highlighted by the WHO …
[HTML][HTML] Evolution of Streptococcus pneumoniae Serotype 3 in England and Wales: A Major Vaccine Evader
Despite its inclusion in pneumococcal conjugate vaccine 13 (PCV13), Streptococcus
pneumoniae serotype 3 remains a major cause of invasive pneumococcal disease in …
pneumoniae serotype 3 remains a major cause of invasive pneumococcal disease in …
Streptococcus pneumoniae serotype distribution and antimicrobial nonsusceptibility trends among adults with pneumonia in the United States, 2009‒2017
Summary Background In the United States, the 13-valent pneumococcal conjugate vaccine
has been recommended for children since 2010 and for adults aged≥ 65 years since 2014 …
has been recommended for children since 2010 and for adults aged≥ 65 years since 2014 …